- Home
- VNDA vs SSSS Comparison
VNDA vs SSSS Comparison
Compare VNDA & SSSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNDA
- SSSS
- Stock Information
- Founded
- VNDA 2002
- SSSS 2010
- Country
- VNDA United States
- SSSS United States
- Employees
- VNDA N/A
- SSSS N/A
- Industry
- VNDA Biotechnology: Pharmaceutical Preparations
- SSSS Finance: Consumer Services
- Sector
- VNDA Health Care
- SSSS Finance
- Exchange
- VNDA Nasdaq
- SSSS Nasdaq
- Market Cap
- VNDA 249.4M
- SSSS 219.3M
- IPO Year
- VNDA 2006
- SSSS N/A
- Fundamental
- Price
- VNDA $5.35
- SSSS $8.88
- Analyst Decision
- VNDA Strong Buy
- SSSS Strong Buy
- Analyst Count
- VNDA 2
- SSSS 4
- Target Price
- VNDA $16.50
- SSSS $9.75
- AVG Volume (30 Days)
- VNDA 557.6K
- SSSS 210.3K
- Earning Date
- VNDA 11-05-2025
- SSSS 11-06-2025
- Dividend Yield
- VNDA N/A
- SSSS 11.01%
- EPS Growth
- VNDA N/A
- SSSS N/A
- EPS
- VNDA N/A
- SSSS 2.22
- Revenue
- VNDA $203,467,000.00
- SSSS $2,784,381.00
- Revenue This Year
- VNDA $15.45
- SSSS $7,183.09
- Revenue Next Year
- VNDA $37.82
- SSSS N/A
- P/E Ratio
- VNDA N/A
- SSSS $4.09
- Revenue Growth
- VNDA 11.78
- SSSS N/A
- 52 Week Low
- VNDA $3.81
- SSSS $4.21
- 52 Week High
- VNDA $5.59
- SSSS $10.05
- Technical
- Relative Strength Index (RSI)
- VNDA 58.73
- SSSS 42.54
- Support Level
- VNDA $5.11
- SSSS $8.75
- Resistance Level
- VNDA $5.45
- SSSS $9.28
- Average True Range (ATR)
- VNDA 0.21
- SSSS 0.33
- MACD
- VNDA -0.02
- SSSS -0.08
- Stochastic Oscillator
- VNDA 42.71
- SSSS 7.69
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.